Indication
Hemophilia Without Inhibitor
1 clinical trial
2 products
Clinical trial
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia AStatus: Terminated, Estimated PCD: 2022-04-06
Product
EloctateProduct
Emicizumab